Human antibodies specific to KDR and uses thereof
US7498414B2 · kind B2 · utility
76Cited by
35References
53Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 4, 2003 |
| Grant date | Mar 3, 2009 |
| Priority date | — |
| Expiry date | Mar 9, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.